S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
NASDAQ:SLRX

Salarius Pharmaceuticals (SLRX) Stock Forecast, Price & News

$1.49
-0.01 (-0.67%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$1.44
$1.50
50-Day Range
$1.37
$2.16
52-Week Range
$1.07
$7.20
Volume
16,400 shs
Average Volume
159,608 shs
Market Capitalization
$3.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Salarius Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Salarius Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.70) to ($4.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars


SLRX stock logo

About Salarius Pharmaceuticals (NASDAQ:SLRX) Stock

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Receive SLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SLRX Stock News Headlines

Is This The End Of Your Retirement?
Soon, the U.S. Government is going to make an announcement that could radically alter your retirement. Two of America's largest banks - Goldman Sachs and J.P. Morgan - have quietly warned their richest clients to prepare for it. The clock is ticking. Find out How to Protect Yourself from the Greatest Crisis Facing Retirees in 70 Years before it's too late.
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
Salarius Pharmaceuticals, Inc. (SLRX)
See More Headlines
Receive SLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SLRX Company Calendar

Last Earnings
3/27/2023
Today
5/29/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLRX
Fax
N/A
Employees
16
Year Founded
2011

Profitability

Net Income
$-31,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.84 million
Book Value
$2.23 per share

Miscellaneous

Free Float
2,434,000
Market Cap
$3.71 million
Optionable
Not Optionable
Beta
0.96

Social Links


Key Executives

  • David J. Arthur
    President, Chief Executive Officer & Director
  • Mark J. Rosenblum
    Chief Financial Officer & Executive Vice President
  • Nadeem Q. Mirza
    Senior Vice President-Clinical Development













SLRX Stock - Frequently Asked Questions

How have SLRX shares performed in 2023?

Salarius Pharmaceuticals' stock was trading at $1.53 on January 1st, 2023. Since then, SLRX shares have decreased by 2.6% and is now trading at $1.49.
View the best growth stocks for 2023 here
.

Are investors shorting Salarius Pharmaceuticals?

Salarius Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 94,700 shares, a decrease of 16.0% from the April 30th total of 112,800 shares. Based on an average daily volume of 92,600 shares, the short-interest ratio is currently 1.0 days. Currently, 4.2% of the shares of the company are short sold.
View Salarius Pharmaceuticals' Short Interest
.

When is Salarius Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our SLRX earnings forecast
.

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announced its earnings results on Monday, March, 27th. The company reported ($2.83) EPS for the quarter, missing analysts' consensus estimates of ($2.16) by $0.67.

What ETF holds Salarius Pharmaceuticals' stock ?

Horizon Kinetics Medical ETF holds 32,400 shares of SLRX stock, representing 0.25% of its portfolio.

When did Salarius Pharmaceuticals' stock split?

Salarius Pharmaceuticals's stock reverse split on Monday, October 17th 2022. The 1-25 reverse split was announced on Monday, October 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).

What is Salarius Pharmaceuticals' stock symbol?

Salarius Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLRX."

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Salarius Pharmaceuticals' stock price today?

One share of SLRX stock can currently be purchased for approximately $1.49.

How much money does Salarius Pharmaceuticals make?

Salarius Pharmaceuticals (NASDAQ:SLRX) has a market capitalization of $3.71 million and generates $1.84 million in revenue each year. The company earns $-31,610,000.00 in net income (profit) each year or ($13.72) on an earnings per share basis.

How can I contact Salarius Pharmaceuticals?

Salarius Pharmaceuticals' mailing address is 2450 Holcombe Blvd. Suite X, Houston TX, 77021. The official website for the company is www.salariuspharma.com. The company can be reached via phone at (832) 834-6992 or via email at jeremy@lifesciadvisors.com.

This page (NASDAQ:SLRX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -